Evidence map›Paper›PMID 41123742›Full record

ReviewCurrent heart failure reports2025

Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor-Myocarditis: Diagnostic and Prognostic Evidence and Limitations.

Joe-Elie Salem, Lauren A Baldassarre, Alban Redheuil, Samia Boussouar, Paaladinesh Thavendiranathan, Adrien Procureur

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Early prediction of synergistic cardiotoxicity induced by PD-1 inhibitors and doxorubicin using cardiacChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joe-Elie SalemDepartment of Pharmacology, Sorbonne Université, INSERM, Clinical Investigation Center Paris-Est, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France. joe-elie.salem@aphp.fr.ORCID http://orcid.org/0000-0002-0331-3307
Lauren A BaldassarreSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.
Alban RedheuilDepartment of Cardiovascular and Thoracic Imaging, Sorbonne Université, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, INSERM 1146, CNRS 7371, Laboratoire d'Imagerie Biomédicale, IHU ICAN, Paris, France.
Samia BoussouarDepartment of Cardiovascular and Thoracic Imaging, Sorbonne Université, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, INSERM 1146, CNRS 7371, Laboratoire d'Imagerie Biomédicale, IHU ICAN, Paris, France.
Paaladinesh ThavendiranathanDepartment of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.
Adrien ProcureurDepartment of Pharmacology, Sorbonne Université, INSERM, Clinical Investigation Center Paris-Est, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewImmune checkpoint inhibitor (ICI)-associated myocarditis (ICI-M) is rare but often severe. Cardiac magnetic resonance imaging (CMR) can detect myocardial edema and injury as well as fibrosis, yet its role in the setting of ICI-M remains uncertain. This review evaluates recent evidence on CMR findings, prognostic markers, and practical limitations in ICI-M. RECENT

findingsT1/T2 mapping and strain analysis may detect myocardial involvement not evident with conventional measures, but sensitivity is variable and affected by scan timing, prior therapies, and protocol heterogeneity. Prognostic associations have been reported for elevated native myocardial T1, septal late gadolinium enhancement (LGE), and impaired strain, though not consistently. In oncology patients, interpretation is further complicated by potential baseline myocardial abnormalities. While CMR can contribute to the diagnostic work-up and risk assessment of ICI-M, current evidence is inconsistent and hampered by methodological limitations. CMR should be timely and findings should be interpreted alongside clinical, biological, ECG, echocardiographic and pathology data. Standardized multicenter prospective studies are needed.

Indexed as

Immune Checkpoint InhibitorsMagnetic Resonance Imaging, CineMyocarditisMyocardiumHumansPrognosisImmune Checkpoint InhibitorsCardiac magnetic resonance imagingImmune checkpoint inhibitorsLate gadolinium enhancementMyocarditisPharmacologyT1 and T2 mapping

Identifiers

PMID41123742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.